PeptiDream Inc. (TYO:4587)
1,126.00
+17.50 (1.58%)
Aug 27, 2026, 10:15 AM JST
PeptiDream Revenue
PeptiDream had revenue of 4.46B JPY in the quarter ending June 30, 2026, with 3.51% growth. This brings the company's revenue in the last twelve months to 19.20B, up 0.62% year-over-year. In the year 2025, PeptiDream had annual revenue of 18.52B, down -60.32%.
Revenue (ttm)
19.20B
Revenue Growth
+0.62%
P/S Ratio
7.42
Revenue / Employee
29.77M
Employees
763
Market Cap
142.52B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 18.52B | -28.16B | -60.32% |
| Dec 31, 2024 | 46.68B | 17.96B | 62.57% |
| Dec 31, 2023 | 28.71B | 1.86B | 6.93% |
| Dec 31, 2022 | 26.85B | 17.49B | 186.70% |
| Dec 31, 2021 | 9.37B | -2.31B | -19.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nxera Pharma | 33.43B |
| GNI Group | 26.53B |
| Heartseed | 3.03B |
| Japan Tissue Engineering | 2.52B |
| AnGes | 962.00M |
| Cuorips | 128.00M |
| Healios K.K. | 59.00M |
| Oncolys BioPharma | 28.55M |
PeptiDream News
- 13 days ago - Q2 2026 PeptiDream Inc. Earnings Presentation Transcript - GuruFocus
- 14 days ago - PeptiDream Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - PeptiDream Quarterly report: Q2 2026 - Filings
- 14 days ago - PeptiDream Slides: Q2 2026 - Filings
- 7 weeks ago - PeptiDream appoints three new executive vice presidents - TheFly
- 2 months ago - PeptiDream Announces First Dosing of Claudin18.2 Targeting Radiopharmaceutical Candidate 64Cu-PD-29875 in Patients with Gastric Cancer - Business Wire
- 2 months ago - PeptiDream, PDRadiopharma and Curium Group Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - Business Wire
- 2 months ago - Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan - GlobeNewsWire